Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Acute Migraine Treatment with Ubrelvy (Ubrogepant)

Treatment Algorithm

  • The American College of Physicians recommends considering gepants like ubrogepant for patients who do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen 2
  • First-line therapy for acute migraine includes NSAIDs (ibuprofen, naproxen, aspirin, diclofenac) with antiemetics if needed, as recommended by the American College of Physicians and supported by evidence from Nature Reviews Neurology 1, 2, 3
  • Second-line therapy for acute migraine includes triptans (sumatriptan, rizatriptan, zolmitriptan, etc.) or combination of triptans with NSAIDs, according to guidelines from the American College of Physicians and Annals of Internal Medicine 1, 2
  • Third-line therapy for acute migraine includes CGRP antagonists (gepants) like ubrogepant or ditans like lasmiditan, as suggested by the American College of Physicians and supported by evidence from Nature Reviews Neurology and Annals of Internal Medicine 1, 2

Special Considerations

  • The CDC recommends avoiding opioids for migraine treatment, instead suggesting triptans, NSAIDs, antiemetics, dihydroergotamine, gepants (including ubrogepant), and lasmiditan, which are associated with improved pain and function with usually mild and transient adverse events 4
  • Gepants like ubrogepant are believed to be non-vasoconstrictive, potentially offering a safer alternative for patients with cardiovascular risk factors, according to the CDC 4

Monitoring and Follow-up

  • The American College of Physicians suggests documenting frequency, severity, and response to treatment, and being aware of medication overuse headache, which can occur if acute medications are used too frequently (≥10 days/month for triptans, ≥15 days/month for NSAIDs) 2
  • Consider preventive therapy if migraines occur frequently (≥2 days/month) despite optimized acute treatment, as recommended by the American College of Physicians and supported by evidence from Nature Reviews Neurology and Annals of Internal Medicine 1, 2